R Estêvão, H Duarte, F Lopes, J Fernandes, E Monteiro
{"title":"肽受体放射性核素治疗头颈部副神经节瘤14例报告。","authors":"R Estêvão, H Duarte, F Lopes, J Fernandes, E Monteiro","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Peptide receptor radionuclide therapy (PRRT) is a very promising treatment option in neuroendocrine tumours, with good results, but there are only few reports regarding its use in paragangliomas.</p><p><strong>Methods: </strong>The authors conducted a retrospective study during the period of May 2011 to February 2014 in an Oncological Centre. Ten patients with jugular-tympanic paragangliomas and four with carotid body paragangliomas were treated with three cycles of Lutetium labelled peptide (177 Lu-DOTATATE). Treatment response was assessed with a PET-CT with 68 Ga-DOTANOC and clinical criteria.</p><p><strong>Results: </strong>Ten of the fourteen patients showed a decrease in the tumor standard uptake value (SUV) after treatment. 90% of patients with Jugulotympanic paragangliomas had symptomatic improvement or stabilization. Patients with carotid body paragangliomas and patients with a low uptake of 68 Ga-DOTANOC had a worse response to the treatment. The tumor SUV value was a predictor of treatment response [R= 0,64; F= 8,212; p= 0,014].</p><p><strong>Conclusion: </strong>Peptide receptor radionuclide therapy can be a therapeutic option in selected cases of head and neck paragangliomas.</p>","PeriodicalId":76469,"journal":{"name":"Revue de laryngologie - otologie - rhinologie","volume":"136 4","pages":"155-8"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Peptide receptor radionuclide therapy in head and neck paragangliomas – Report of 14 cases.\",\"authors\":\"R Estêvão, H Duarte, F Lopes, J Fernandes, E Monteiro\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Peptide receptor radionuclide therapy (PRRT) is a very promising treatment option in neuroendocrine tumours, with good results, but there are only few reports regarding its use in paragangliomas.</p><p><strong>Methods: </strong>The authors conducted a retrospective study during the period of May 2011 to February 2014 in an Oncological Centre. Ten patients with jugular-tympanic paragangliomas and four with carotid body paragangliomas were treated with three cycles of Lutetium labelled peptide (177 Lu-DOTATATE). Treatment response was assessed with a PET-CT with 68 Ga-DOTANOC and clinical criteria.</p><p><strong>Results: </strong>Ten of the fourteen patients showed a decrease in the tumor standard uptake value (SUV) after treatment. 90% of patients with Jugulotympanic paragangliomas had symptomatic improvement or stabilization. Patients with carotid body paragangliomas and patients with a low uptake of 68 Ga-DOTANOC had a worse response to the treatment. The tumor SUV value was a predictor of treatment response [R= 0,64; F= 8,212; p= 0,014].</p><p><strong>Conclusion: </strong>Peptide receptor radionuclide therapy can be a therapeutic option in selected cases of head and neck paragangliomas.</p>\",\"PeriodicalId\":76469,\"journal\":{\"name\":\"Revue de laryngologie - otologie - rhinologie\",\"volume\":\"136 4\",\"pages\":\"155-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue de laryngologie - otologie - rhinologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue de laryngologie - otologie - rhinologie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Peptide receptor radionuclide therapy in head and neck paragangliomas – Report of 14 cases.
Background: Peptide receptor radionuclide therapy (PRRT) is a very promising treatment option in neuroendocrine tumours, with good results, but there are only few reports regarding its use in paragangliomas.
Methods: The authors conducted a retrospective study during the period of May 2011 to February 2014 in an Oncological Centre. Ten patients with jugular-tympanic paragangliomas and four with carotid body paragangliomas were treated with three cycles of Lutetium labelled peptide (177 Lu-DOTATATE). Treatment response was assessed with a PET-CT with 68 Ga-DOTANOC and clinical criteria.
Results: Ten of the fourteen patients showed a decrease in the tumor standard uptake value (SUV) after treatment. 90% of patients with Jugulotympanic paragangliomas had symptomatic improvement or stabilization. Patients with carotid body paragangliomas and patients with a low uptake of 68 Ga-DOTANOC had a worse response to the treatment. The tumor SUV value was a predictor of treatment response [R= 0,64; F= 8,212; p= 0,014].
Conclusion: Peptide receptor radionuclide therapy can be a therapeutic option in selected cases of head and neck paragangliomas.